GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mineralys Therapeutics Inc (NAS:MLYS) » Definitions » 50-Day SMA

Mineralys Therapeutics (Mineralys Therapeutics) 50-Day SMA : $12.72 (As of May. 27, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mineralys Therapeutics 50-Day SMA?

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2024-05-27), Mineralys Therapeutics's 50-Day SMA is $12.72. It's 20-Day SMA is $13.09 and 200-Day SMA is $10.88.


Competitive Comparison of Mineralys Therapeutics's 50-Day SMA

For the Biotechnology subindustry, Mineralys Therapeutics's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mineralys Therapeutics's 50-Day SMA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Mineralys Therapeutics's 50-Day SMA falls into.



Mineralys Therapeutics  (NAS:MLYS) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mineralys Therapeutics  (NAS:MLYS) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.


Mineralys Therapeutics 50-Day SMA Related Terms

Thank you for viewing the detailed overview of Mineralys Therapeutics's 50-Day SMA provided by GuruFocus.com. Please click on the following links to see related term pages.


Mineralys Therapeutics (Mineralys Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
Executives
Jon Congleton director, officer: Chief Executive Officer 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Glenn Sblendorio director 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
David Malcom Rodman officer: Chief Medical Officer 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Srinivas Akkaraju director, 10 percent owner 565 EVERETT AVENUE, PALO ALTO CA 94301
Hbm Healthcare Investments (cayman) Ltd. 10 percent owner GOVERNORS SQUARE, 23 LIME TREE BAY AVE.,, PO BOX 30852, GRAND CAYMAN E9 KY1-1204
Adam Scott Levy officer: CFO, Chief Bus. Off. and Secy. C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
Catalys Pacific Fund, Lp 10 percent owner 301 9-19 HACHIYAMA, SHIBUYA, TOKYO M0 150-0035
Olivier Litzka director C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Takeshi Takahashi director C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Brian Taylor Slingsby director, 10 percent owner C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Ra Capital Nexus Fund Iii, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Samsara Biocapital, L.p. 10 percent owner 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Alexander Asam director C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361

Mineralys Therapeutics (Mineralys Therapeutics) Headlines

From GuruFocus